{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:08:35Z","timestamp":1740107315891,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Cognitive impairment in chronic diseases such as psoriasis is an increasing clinical challenge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To assess the frequency and extent of difficulties in cognitive functioning in people with psoriasis compared to healthy people.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>The systematic review was carried out on the 23rd July, 2021 by two trained psychologists resulting in a selection of 11 studies on 971 patients with psoriasis and 10,242 controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A review of the studies showed irregularities in many cognitive domains, including working memory processes, executive functions, long-term verbal memory, attention, and the visuospatial domain. Depending on the methods used to assess cognitive dysfunctions and the characteristics of patients in different studies, large differences in the frequency of cognitive impairment in patients with psoriasis were observed, ranging from 0 to 91.9%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The authors conclude that there is a need for longitudinal studies to identify factors important for the development and persistence of cognitive impairment in psoriatic patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-022-11317-2","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T21:02:33Z","timestamp":1660078953000},"page":"6269-6278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cognitive impairment in psoriasis patients: a systematic review of case\u2013control studies"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7667-5803","authenticated-orcid":false,"given":"Daniel","family":"Pankowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8236-4363","authenticated-orcid":false,"given":"K.","family":"Wytrychiewicz-Pankowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2049-942X","authenticated-orcid":false,"given":"W.","family":"Owczarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"issue":"19","key":"11317_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006","journal-title":"JAMA"},{"issue":"2","key":"11317_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM (2017) A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 31(2):205\u2013212. https:\/\/doi.org\/10.1111\/jdv.13854","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"11317_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jaut.2009.12.001","volume":"34","author":"V Chandran","year":"2010","unstructured":"Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34(3):314\u2013321. https:\/\/doi.org\/10.1016\/j.jaut.2009.12.001","journal-title":"J Autoimmun"},{"issue":"6","key":"11317_CR4","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaad.2015.02.1095","volume":"72","author":"AW Armstrong","year":"2015","unstructured":"Armstrong AW, Guerin A, Sundaram M et al (2015) Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol 72(6):968\u2013977. https:\/\/doi.org\/10.1016\/j.jaad.2015.02.1095","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"11317_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00403-018-1832-x","volume":"310","author":"Z Kwan","year":"2018","unstructured":"Kwan Z, Bong YB, Tan LL, Lim SX, Yong ASW, Ch\u2019ng CC et al (2018) Determinants of quality of life and psychological status in adults with psoriasis. Arch Dermatol Res 310(5):443\u2013451. https:\/\/doi.org\/10.1007\/s00403-018-1832-x","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"11317_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/bjd.17004","volume":"180","author":"R Parisi","year":"2019","unstructured":"Parisi R, Webb RT, Kleyn CE, Carr MJ, Kapur N, Griffiths CEM, Ashcroft DM (2019) Psychiatric morbidity and suicidal behaviour in psoriasis: a primary care cohort study. Br J Dermatol 180(1):108\u2013115. https:\/\/doi.org\/10.1111\/bjd.17004","journal-title":"Br J Dermatol"},{"issue":"1","key":"11317_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/bjd.19025","volume":"184","author":"H Yen","year":"2021","unstructured":"Yen H, Yen H, Chi CC (2021) Is psoriasis associated with dementia or cognitive impairment? A critically appraised topic. Br J Dermatol 184(1):34\u201342. https:\/\/doi.org\/10.1111\/bjd.19025","journal-title":"Br J Dermatol"},{"issue":"12","key":"11317_CR8","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/annonc\/mdz410","volume":"30","author":"M Lange","year":"2019","unstructured":"Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L et al (2019) Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 30(12):1925\u20131940. https:\/\/doi.org\/10.1093\/annonc\/mdz410","journal-title":"Ann Oncol"},{"issue":"5","key":"11317_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jamda.2017.01.014","volume":"18","author":"AM Yohannes","year":"2017","unstructured":"Yohannes AM, Chen W, Moga AM, Leroi I, Connolly MJ (2017) Cognitive impairment in chronic obstructive pulmonary disease and chronic heart failure: a systematic review and meta-analysis of observational studies. J Am Med Dir Assoc 18(5):451. https:\/\/doi.org\/10.1016\/j.jamda.2017.01.014 (e1)","journal-title":"J Am Med Dir Assoc"},{"issue":"13","key":"11317_CR10","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1016\/j.cgh.2020.03.033","volume":"18","author":"JS Bajaj","year":"2020","unstructured":"Bajaj JS, Duarte-Rojo A, Xie JJ, Acharya C, Wade JB, Robles C et al (2020) Minimal hepatic encephalopathy and mild cognitive impairment worsen quality of life in elderly patients with cirrhosis. Clin Gastroenterol Hepatol 18(13):3008\u20133016. https:\/\/doi.org\/10.1016\/j.cgh.2020.03.033","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"11317_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0304-3959(01)00457-2","volume":"96","author":"SC Brown","year":"2002","unstructured":"Brown SC, Glass JM, Park DC (2002) The relationship of pain and depression to cognitive function in rheumatoid arthritis patients. Pain 96(3):279\u2013284. https:\/\/doi.org\/10.1016\/S0304-3959(01)00457-2","journal-title":"Pain"},{"issue":"5","key":"11317_CR12","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.neuron.2011.12.033","volume":"73","author":"EY Yuen","year":"2012","unstructured":"Yuen EY, Wei J, Liu W, Zhong P, Li X, Yan Z (2012) Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 73(5):962\u2013977. https:\/\/doi.org\/10.1016\/j.neuron.2011.12.033","journal-title":"Neuron"},{"issue":"1","key":"11317_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-77866-6","volume":"10","author":"T Form\u00e1nek","year":"2020","unstructured":"Form\u00e1nek T, Csajb\u00f3k Z, Wolfov\u00e1 K, Ku\u010dera M, Tom S, Aarsland D, Cermakova P (2020) Trajectories of depressive symptoms and associated patterns of cognitive decline. Sci Rep 10(1):1\u201311","journal-title":"Sci Rep"},{"issue":"2","key":"11317_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1192\/bjp.2017.26","volume":"212","author":"N Schmitz","year":"2018","unstructured":"Schmitz N, Desch\u00eanes SS, Burns RJ, Danna SM, Franco OH, Ikram MA et al (2018) Cardiometabolic dysregulation and cognitive decline: potential role of depressive symptoms. Br J Psychiatry 212(2):96\u2013102","journal-title":"Br J Psychiatry"},{"issue":"6","key":"11317_CR15","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/jid.2013.508","volume":"134","author":"EA Dowlatshahi","year":"2014","unstructured":"Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T (2014) The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Investig Dermatol 134(6):1542\u20131551","journal-title":"J Investig Dermatol"},{"issue":"1\u20132","key":"11317_CR16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cell.2018.10.049","volume":"176","author":"EM Gibson","year":"2019","unstructured":"Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Pallegar PN et al (2019) Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive Impairment. Cell 176(1\u20132):43\u201355. https:\/\/doi.org\/10.1016\/j.cell.2018.10.049","journal-title":"Cell"},{"issue":"7","key":"11317_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed1000097","journal-title":"PLoS Med"},{"issue":"4","key":"11317_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40257-016-0187-3","volume":"17","author":"E Colgecen","year":"2016","unstructured":"Colgecen E, Celikbilek A, Keskin DT (2016) Cognitive impairment in patients with psoriasis: a cross-sectional study using the montreal cognitive assessment. Am J Clin Dermatol 17(4):413\u2013419. https:\/\/doi.org\/10.1007\/s40257-016-0187-3","journal-title":"Am J Clin Dermatol"},{"key":"11317_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.046","author":"E Pezzolo","year":"2018","unstructured":"Pezzolo E, Mutlu U, Vernooij MW, Dowlatshahi EA, Gisondi P, Girolomoni G et al (2018) Psoriasis is not associated with cognition, brain imaging markers, and risk for dementia: the Rotterdam Study. J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.046","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"11317_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11011-011-9269-3","volume":"27","author":"V Felipo","year":"2012","unstructured":"Felipo V, Urios A, Montesinos E, Molina I, Garcia-Torres ML, Civera M et al (2012) Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab Brain Dis 27(1):51\u201358. https:\/\/doi.org\/10.1007\/s11011-011-9269-3","journal-title":"Metab Brain Dis"},{"issue":"6","key":"11317_CR21","first-page":"483","volume":"98","author":"L Marek","year":"2011","unstructured":"Marek L, Placek W, Borkowska A (2011) Cognitive impairment and affective temperament in patients with psoriasis. Przegl Dermatol 98(6):483","journal-title":"Przegl Dermatol"},{"issue":"1","key":"11317_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000357220","volume":"228","author":"P Gisondi","year":"2014","unstructured":"Gisondi P, Sala F, Alessandrini F, Avesani V, Zoccatelli G, Beltramello A et al (2014) Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology 228(1):78\u201385. https:\/\/doi.org\/10.1159\/000357220","journal-title":"Dermatology"},{"issue":"2","key":"11317_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5114\/ada.2017.67074","volume":"34","author":"L Marek-J\u00f3zefowicz","year":"2017","unstructured":"Marek-J\u00f3zefowicz L, Jaracz M, Placek W, Czajkowski R, Borkowska A (2017) Cognitive impairment in patients with severe psoriasis. Postepy Dermatol Alergol 34(2):120 (PMID: 28507490)","journal-title":"Postepy Dermatol Alergol"},{"key":"11317_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jpsychores.2017.12.011","volume":"105","author":"M Innamorati","year":"2018","unstructured":"Innamorati M, Quinto RM, Lester D, Iani L, Graceffa D, Bonifati C (2018) Cognitive impairment in patients with psoriasis: a matched case-control study. J Psychosom Res 105:99\u2013105. https:\/\/doi.org\/10.1016\/j.jpsychores.2017.12.011","journal-title":"J Psychosom Res"},{"issue":"4","key":"11317_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/24750573.2019.1589176","volume":"29","author":"E Deveci","year":"2019","unstructured":"Deveci E, Kocacenk T, \u015eahan E, Y\u0131lmaz O, \u00d6zt\u00fcrk A, K\u0131rp\u0131nar \u0130 (2019) Oxidative stress and inflammatory response in patients with psoriasis; is there any relationship with psychiatric comorbidity and cognitive functions? Psychiatr Cli Psychopharmacol 29(4):682\u2013695. https:\/\/doi.org\/10.1080\/24750573.2019.1589176","journal-title":"Psychiatr Cli Psychopharmacol"},{"key":"11317_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024833","author":"M Di Carlo","year":"2021","unstructured":"Di Carlo M, Becciolini A, Incorvaia A, Beci G, Smerilli G, Biggioggero M et al (2021) Mild cognitive impairment in psoriatic arthritis: prevalence and associated factors. Medicine. https:\/\/doi.org\/10.1097\/MD.0000000000024833","journal-title":"Medicine"},{"issue":"8","key":"11317_CR27","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.4103\/jfmpc.jfmpc_104_20","volume":"9","author":"K Padma","year":"2020","unstructured":"Padma K, Nanaware SS, Yadiyal A, Mathai PJ (2020) Cognitive impairment in patients with psoriasis: A clinical study in teaching hospital. J Family Med Prim Care 9(8):4001. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_104_20","journal-title":"J Family Med Prim Care"},{"key":"11317_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-021-01644-y","author":"LOKL Garcia","year":"2021","unstructured":"Garcia LOKL, J\u00fanior ATS, dos Santos G\u00f3mez DC, Yoshikawa GSS, Kamikoga CK, Vitturi BK (2021) Cognitive impairment in patients with psoriatic arthritis. Acta Neurol Belg. https:\/\/doi.org\/10.1007\/s13760-021-01644-y","journal-title":"Acta Neurol Belg"},{"issue":"1","key":"11317_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00520-009-0625-3","volume":"18","author":"HS Jim","year":"2010","unstructured":"Jim HS, Small BJ, Patterson S, Salup R, Jacobsen PB (2010) Cognitive impairment in men treated with luteinizing hormone\u2013releasing hormone agonists for prostate cancer: a controlled comparison. Support Care Cancer 18(1):21\u201327. https:\/\/doi.org\/10.1007\/s00520-009-0625-3","journal-title":"Support Care Cancer"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11317-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T12:05:31Z","timestamp":1667131531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11317-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["11317"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11317-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"13 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Witold Owczarek has worked as a Consultant or Speaker and participated as Principal Investigator or Subinvestigator in clinical trials sponsored by AbbVie, Alfasigma, Almirall, Bioderma,\u00a0Bristol-Myers Squibb,\u00a0Egis, Eli Lilly, Galenica, Galderma, Janssen-Cilag, Leo Pharma, Medac GmbH, Mylan, Novartis, Pfizer, Pierre-Fabre, Roche, Sandoz, Teva Pharmaceuticals,\u00a0UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB statement"}}]}}